Regeneron Pharmaceuticals' Careers NewsEmployer Directory Featured Listing, Feeds and Subscriptions

The latest Regeneron Pharmaceuticals careers news and job posts. Subscribe for daily updates to your inbox, mobile device and/or smartphone.

  Jobs Feed | Subscribe  

Known for its scientific and operational excellence, Regeneron is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Rege...
Posted: October 16, 2018, 5:08 pm
The Regeneron Genetics Center (RGC) is a wholly-owned subsidiary of the Company, whose goals are to apply large scale human genetics to identify new drug targets and to guide the development of therapeutics programs and precision medicine. Buildin...
Posted: October 16, 2018, 5:08 pm
Regeneron offers a unique, world-class opportunity for interested candidates. Regeneron has been consistently ranked a “Top Employer” in Science Magazine’s rankings for pharmaceutical and biotechnology companies. Regeneron is fully committed to ...
Posted: October 16, 2018, 5:08 pm
Known for its scientific and operational excellence, Regeneron is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Rege...
Posted: October 16, 2018, 5:08 pm
The Regeneron Genetics Center (RGC) is a wholly-owned subsidiary of the Company, whose goals are to apply large scale human genetics to identify new drug targets and to guide the development of therapeutics programs and precision medicine. Buildin...
Posted: October 16, 2018, 5:08 pm

Viewing page 1 of 87|Next Page

  Newsfeed | Subscribe  

Regeneron Pharmaceuticals (REGN) jumped Tuesday after its blockbuster hopeful Dupixent showed promise in treating nasal polyps. The study pitted Dupixent against a placebo in treating nasal polyps in ...
Posted: October 16, 2018, 11:07 am
Regeneron Pharmaceuticals (NASDAQ:REGN) and development partner Sanofi (NYSE:SNY) announce positive results from two Phase 3 clinical trials, SINUS-24 and SINUS-52, evaluating DUPIXENT (dupilumab ...
Posted: October 16, 2018, 4:21 am
In afternoon trading on Tuesday, Healthcare stocks are the best performing sector, higher by 2.7%. Within that group, Regeneron Pharmaceuticals, Inc. (Symbol: REGN) and Alexion Pharmaceuticals Inc. (S...
Posted: October 15, 2018, 11:31 pm
(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi said that both pivotal Phase 3 placebo-controlled trials evaluating Dupixent or dupilumab in adults with inadequately-controlled ...
Posted: October 15, 2018, 10:20 pm
Kovack Advisors Inc. cut its stake in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 31.0% in the third quarter, Holdings Channel reports. The fund owned 511 shares of the biopharmaceutical company’s ...
Posted: October 13, 2018, 2:29 am

Viewing page 1 of 3|Next Page